Share on Google Plus Share on Twitter Share on Facebook Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend

Printer Friendly Page Save As Favorite View Favorites (# of views)   2 comments
OpEdNews Op Eds

New Zealand, legal highs and sensible supply-side policies

By Kasia Malinowska-Sempruch  Posted by Patrick Gallahue (about the submitter)     Permalink
      (Page 2 of 2 pages) Become a premium member to see this article and all articles as one long page.
Related Topic(s): ; , Add Tags Add to My Group(s)

View Ratings | Rate It

opednews.com Headlined to H3 1/26/13

This comes very close to acknowledging that potentially harmful legal highs are a byproduct of prohibition.

Existing drug policies are generally rooted in the false assumption that if you make something illegal, people won't use it and hence they will be protected from its harms. In the end, the exact opposite tends to be true because once something is illegal, the standard policy levers of government are out of reach.

As the All-Party group writes, "A useful feature of New Zealand's planned policy is to assess both the harms arising from a particular substance and the harms arising from controlling it."

Might we the UK also be better served by begin regulatory processes to understand the drugs that people are taking and developing policies that address their relative risks?

That is precisely what New Zealand has started doing. It's worth a closer look.

Kasia Malinowska-Sempruch is the director of Open Society Foundations Global Drug Policy Program

Next Page  1  |  2

 

- Advertisement -

View Ratings | Rate It

/* The Petition Site */
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact EditorContact Editor

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

The International Narcotics Control Board Strains its Limited Credibility

On Drug Policy, Europe Shows Us the Money--and It's Ugly